Acquired Company

BioMarin acquired Inozyme Pharma, Inc. on 7/1/2025 for $4.00 per share in cash, representing a total transaction value of about $270 million.

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Show more

321 Summer Street, Boston, MA, 02210, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

258.2M

52 Wk Range

$0.72 - $6.24

Previous Close

$4.00

Open

$4.00

Volume

N/A

Day Range

$4.00 - $4.00

Enterprise Value

220.4M

Cash

84.78M

Avg Qtr Burn

-24.13M

Insider Ownership

1.26%

Institutional Own.

94.29%

Qtr Updated

03/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease, ABCC6 Deficiency	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INZ-701 (ENPP1-Fc) Details ENPP1 deficiency, Genetic disorder, Rare genetic disease	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INZ-701 (ENPP1-Fc) Details End-stage renal disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.